BDR Pharma to acquire stake in Acme’s oral solid formulations business

Published 09 Nov 2026, 21:35 IST

What each side is saying

One outlet's own words from each side of the spectrum. Quoted, not summarised.

left · 1 outlet

BDR Pharma to acquire stake in Acme’s oral solid formulations business

— The Hindu
right · 1 outlet

The transaction values the business at about ₹2,370 crore ($250 million), said sources close to the deal

— The Hindu BusinessLine

Coverage arrived over 2 hours — first from The Hindu BusinessLine, latest from The Hindu.

✓ Corroborated Coverage ⚡ Cross-Spectrum Consensus 2 news outlets reporting

Verified by independent outlets with different editorial leanings.

Based on 2 reporting publishers

L 50%

R 50%

Left / Center-Left 1 (50%)

Center 0 (0%)

Center-Right / Right 1 (50%)

The Hindu BusinessLine Center-Right The Hindu Group (Kasturi & Sons) 09 Nov 2026, 18:44 IST

BDR Pharma buys majority stake in oral care biz of Acme Formulation

The transaction values the business at about ₹2,370 crore ($250 million), said sources close to the deal

Compare on Varta → Read at The Hindu BusinessLine ↗
2 hours later
The Hindu Center-Left Kasturi & Sons Ltd. Current article 09 Nov 2026, 21:35 IST

BDR Pharma to acquire stake in Acme’s oral solid formulations business

Read at The Hindu ↗